This usually settles within a day or two
Although clinical trials havent shown this to be significant with Semaglutide in particular, its best to use caution when taking any oral medication.
Understanding your peptide pathway predispositions may empower your provider to recommend lower starting doses, extended titration timelines, or oral versus injectable formulations tailored to your unique neurovascular and metabolic profile
What guidelines and real-world practice say Despite the lack of direct trials, major guidelines support: Using the lowest effective dose Shared decision-making Individualised plans In real-world practice, many clinicians: Use a maintenance phase Reduce dose gradually Monitor appetite, weight stability, and wellbeing Adjust based on how the person feels, not just the scales This approach is not because we have perfect data, but because it aligns with physiology, patient experience, and common sense
Alternatives for special cases